JRS Pharma & Gujarat Microwax Unveil New Manufacturing Facility
JRS Pharma, a renowned leader in the excipient manufacturing sector, has partnered with Gujarat Microwax to launch a cutting-edge manufacturing facility for cotton-based croscarmellose sodium in Mehsana. This facility represents their fourth plant in India, highlighting their commitment to strengthening the local manufacturing landscape. The grand opening was graced by senior executives from over 50 prominent pharmaceutical companies, among other distinguished guests.
Meeting the Growing Demand for Excipients in India
With a legacy spanning 149 years, JRS Pharma has been at the forefront of plant fiber technology innovations. Their diverse excipients portfolio encompasses high functionality excipients, binders, disintegrants, lubricants, functional fillers, thickeners, stabilizers, carriers, and coatings, serving the global health science industry. Rohit Raut, Managing Director of Rettenmaier India, the Indian subsidiary of JRS Group, highlighted the burgeoning excipients market in India driven by increasing health awareness, rising disposable incomes, and an ageing population. He emphasized that the new facility is poised to meet the accelerating demand for functional excipients in the region.
Elevating Quality and Reducing Import Dependency
Manas Jhajharia, Director of Gujarat Microwax, stressed the critical need for quality enhancement within the Indian excipient industry, which currently holds less than 1% of the global market share. He underscored that the Mehsana plant boasts a world-class production facility designed to meet international standards, thereby enhancing the export potential of quality excipients from India. In addition to their extensive range of excipients, JRS Pharma provides technical support and biopharma services to address diverse customer needs and formulation challenges. This strategic expansion marks a pivotal move towards achieving self-sufficiency in the Indian excipient industry.
